About Caris Life Sciences
Caris Life Sciences is a next-generation AI TechBio company and precision medicine pioneer founded in 2008 with the mission to improve the human condition. The company revolutionizes cancer care by providing physicians and patients with comprehensive molecular profiling services that analyze cancer at the DNA, RNA, and protein levels. Caris has built one of the world's largest multimodal databases, containing over 790,000 matched patient records combining molecular and clinical outcomes data. The company's flagship products include MI Profile for tissue-based whole exome and whole transcriptome sequencing, Caris Assure for blood-based profiling, and AI-powered solutions like Caris GPSai and Caris FOLFIRSTai. Through the Caris Precision Oncology Alliance, the company collaborates with over 95 leading cancer institutions worldwide, including 45+ NCI-designated cancer centers, to advance precision oncology research and clinical care. Caris serves the full cancer care continuum from disease detection through therapy selection to treatment monitoring, supporting oncologists, health systems, biopharma companies, and research institutions globally.
Mission & Story
Mission
Caris was built for one reason — to improve the human condition. Through tireless efforts, breakthrough molecular science, and a passionate commitment to quality, we remain steadfastly focused on the most important part of our work — the patient.
Founding Story
Caris was founded in 2008 with a simple but powerful purpose – to help improve the lives of as many people as possible. The company was established by David Dean Halbert, who serves as Chairman, Founder and CEO.
Clinical Focus
Medical conditions and clinical areas addressed by Caris Life Sciences.
Who It Serves
Milestones & Awards
Recent Milestones
Announced dual listing on NYSE Texas (June 2026), announced share repurchase program (June 2026), expanded database to 790,000+ matched patient records
Key Partnerships
Company Details
- Founded
- 2008
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Cognoa
Cognoa is an early childhood development and pediatric behavioral health company developing digital diagnostics and therapeutics. Their flagship product, Canvas Dx, is the first FDA-authorized AI-powered diagnostic solution for autism in children ages 1.5-6 years, enabling diagnosis within days instead of months or years.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.